June 2022 - CanadianCannabisWire

ThursdayJun 30, 2022 9:45 am

Flora Growth Corp. (NASDAQ: FLGC) Anticipates Continued Growth for Cannabis Operations Under New Colombian Administration

Flora Growth is a cannabis cultivator and distributor with a base of operations in Colombia’s fertile growing climate, capable of feeding the company’s expanding international supply chain Colombia has undergone a number of regulatory changes in recent years as it emerges from the shadows of years-long drug wars and embraces a growing global acceptance of cannabis products The South American country voted in a new presidential administration in June, and Flora Growth is applauding the president-elect’s continued openness to international cannabis trade Flora Growth announced significant revenue growth during its year-end financial reporting in May, and the company stated it…

WednesdayJun 29, 2022 11:15 am

New Agreements Signed Between Lexaria Bioscience Corp. (NASDAQ: LEXX) and BevNology LLC; Pre-IND Meeting Request Filed with FDA

The two companies signed a manufacturing operating agreement and a commercial agreement Lexaria sent a pre-IND meeting request letter to the US FDA and plans to file the full IND application in late 2022/early 2023 The FDA has acknowledged Lexaria's pre-IND request and responded with conditions prior to the target date of July 30, 2022 Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has recently announced signing two agreements with BevNology LLC, the product and development arm of InterContinental Beverage Capital (“IBC”), operating its state-of-the-art lab and manufacturing facility just outside of Atlanta, Georgia. This announcement only…

TuesdayJun 28, 2022 1:30 pm

Zacks Report Highlights Flora Growth Corp. (NASDAQ: FLGC) Aspiring to Benefit from First Mover Advantage in Multiple Cannabis Market Categories

Flora’s 2021 acquisitions allowed it to expand its operations beyond North America and into Europe Acquisitions have also contributed to 450% YOY revenue growth for Q1 2022 Its management is confident that the foundation laid down so far will yield growth for 2022 and subsequent financial years Flora has also reiterated 2022 revenue guidance of $35 million to $45 million 2021 was an excellent year for Flora Growth (NASDAQ: FLGC). According to a recent research report from Zacks (https://cnw.fm/bWU0H), the company possesses a number of important qualities pointing to continued significant growth following a strong 2021. Flora Growth management even…

MondayJun 27, 2022 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Reach of its Drug Delivery Technology Through Newly Inked Agreements with Beverage Developer BevNology

Drug delivery technology innovator Lexaria Bioscience has developed a patented technology showing superiority in animal and human testing as a means of improving existing drug brands’ performance and establishing new solutions for unmet medical needs The company recently announced agreements with beverage developer BevNology to expand production capabilities for Lexaria's own growing list of B2B clientele and empowering BevNology to offer DehydraTECH products with active ingredients derived from hemp including CBD under BevNology and partnered brands The technology is called DehydraTECH — improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery Lexaria also…

FridayJun 24, 2022 11:15 am

Flora Growth Corp. (NASDAQ: FLGC) Authorizes the Repurchase of up to $5 Million Shares

Flora Growth Corp. announced that the Company Board has authorized the repurchase of up to $5 million of its outstanding common shares Luis Merchan, Flora’s Chairman and CEO, said that Flora is executing its growth plans while simultaneously improving gross profit margins and reducing corporate overhead expenses At the closing of 2021, the company announced a 2022 revenue guidance projection of $35-45 million Flora Growth (NASDAQ: FLGC) is a global leader in the cultivation, marketing, and distribution of premium-quality cannabis products and brands at below-market prices. Flora Growth recently announced that the company’s Board of Directors (the "Board") has authorized…

ThursdayJun 23, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Grants Licenses to Three Companies for the Month of June; Looks to Follow Through with its Scheduled 2022 Clinical Studies

Lexaria sold Premier Wellness Science Co. exclusive rights to use its patented DehyraTECH(TM) in Japan in a variety of CBD products Valcon Medical A/S also signed an agreement with Lexaria to use its platform for medical cannabis applications in Europe AnodGen Bioceuticals received a pharmaceutical license to use the platform for manufacturing and distributing CBD API powders in Europe, Australia, and New Zealand Lexaria Bioscience (NASDAQ: LEXX) kicked off the month by announcing an exclusive license to Premier Wellness Science Co. for the use of its patented DehydraTECH(TM) technology in Japan in a variety of CBD products. Announced on June…

WednesdayJun 22, 2022 9:00 am

Flora Growth Corp. (NASDAQ: FLGC) Closes the First Half of 2022 with UK Product Launch, Successful Brand Acquisition, and a Collaboration with Ricky Williams’ Cannabis Brand, Highsman

Flora’s collaboration with Highsman seeks to elevate both Highsman and Vessel, Flora’s accessories brand, thereby inspiring greatness and creating an experience worth sharing The company’s acquisition of Masaya allows it to deliver on its promise to invest in safe, thorough, and cutting-edge cannabis research Flora’s product launch on Amazon.co.uk marks a big step in operations expansion in Europe The first half of 2022 has been successful for Flora Growth (NASDAQ: FLGC). At the beginning of the year, the company’s management noted how the cannabis sector was ripe for the picking. They noted how great brands and cost advantages are optimal…

TuesdayJun 21, 2022 9:45 am

Expanding Array of API Enhancements Through Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Patented Drug Technology Bodes Well for New Patient Solutions

Drug bioavailability enhancement technology developer Lexaria Bioscience is working to increase the number of potential new solutions to unmet medical needs and improving existing treatments for other chronic conditions Lexaria’s patented DehydraTECH solution transforms a wide variety of orally and topically administered products into enhanced solutions that make the active pharmaceutical ingredients (“APIs”) more rapidly available and effective at lower doses DehydraTECH-enhanced products have also demonstrated the ability to cross the blood-brain barrier through fatty acid transport proteins The company’s ongoing series of tests of different DehydraTECH-enhanced products has led to a pre-IND filing with the FDA for a prospective…

FridayJun 17, 2022 9:00 am

Flora Growth Corp. (NASDAQ: FLGC) Achieves Key Milestone in Global Expansion Plan with JustCBD Launch on Amazon UK

Flora Growth completed the acquisition of Just Brands LLC and High Roller Private Label LLC, owners of the JustCBD brand, on February 28, 2022 The company then expanded its operational footprint in Europe and the UK in May 2022 to further its international growth strategy JustCBD products, including gummies and tinctures, will be available on www.Amazon.co.uk starting this month in a pilot-only program Flora Growth is optimistic that this launch will allow the company to reach a larger consumer base as it works towards further expanding its operations across Europe On February 28, 2022, Flora Growth (NASDAQ: FLGC) completed the…

WednesdayJun 15, 2022 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Initiates Communication with the FDA Concerning Potential Treatment for Hypertension; Out-Licenses Its DehydraTECH Technology to International Markets

Lexaria, a global innovator of drug delivery platforms, recently filed a pre-IND meeting request letter with the FDA, initiating communication regarding the development of its DehydraTECH-CBD as a treatment for hypertension The company has been undertaking preparatory programs in readiness for the meeting, as well as an IND application filing The pre-IND meeting will confirm the details of the company’s IND-enabling program Lexaria also announced it had licensed its DehydraTECH technology to AnodGen, with the announcement following similar out-licensing agreements with Valcon Medical and Premier Science Early last September, global innovator Lexaria Bioscience (NASDAQ: LEXX) was pleased to announce it…

News and Publishing Service for Cannabis Related, Canadian Companies

Contact us: 905.674.5977

Month: June 2022